Supernus Pharmaceuticals, Inc. (SUPN)
Stock Price:
$23.29 USD
0.21 (0.91%)
Updated Aug 10, 2020 2:10 PM EDT - Market open
Key Info
| Market Cap |
1.22B |
| Revenue (ttm) |
402.26M |
| Net Income (ttm) |
116.23M |
| Shares Out |
52.54M |
| EPS (ttm) |
2.16 |
| PE Ratio |
10.78 |
| Forward PE |
21.28 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$23.29 |
| Previous Close |
$23.08 |
| Change ($) |
0.21 |
| Change (%) |
0.91% |
| Day's Open |
23.25 |
| Day's Range |
23.02 - 23.71 |
| Day's Volume |
166,668 |
| 52-Week Range |
13.12 - 29.81 |
More Stats
| Market Cap |
1.22B |
| Enterprise Value |
1.20B |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
52.54M |
| Float |
47.65M |
| EPS (basic) |
2.21 |
| EPS (diluted) |
2.16 |
| FCF / Share |
2.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
9.27% |
| FCF Yield |
9.32% |
| Payout Ratio |
n/a |
| Shares Short |
4.46M |
| Short Ratio |
8.83 |
| Short % of Float |
12.97% |
| Beta |
1.55 |
| PE Ratio |
10.78 |
| Forward PE |
21.28 |
| P/FCF Ratio |
10.73 |
| PS Ratio |
3.04 |
| PB Ratio |
1.99 |
| Revenue |
402.26M |
| Operating Income |
152.16M |
| Net Income |
116.23M |
| Free Cash Flow |
114.00M |
| Net Cash |
20.84M |
| Net Cash / Share |
0.40 |
| Gross Margin |
93.50% |
| Operating Margin |
37.83% |
| Profit Margin |
28.90% |
| FCF Margin |
28.34% |
| ROA |
8.59% |
| ROE |
21.26% |
| ROIC |
15.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$29.00*
(24.52% upside)
Low
24.0
Current: $23.29
High
33.0
Target: 29.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 393 | 409 | 302 | 215 | 147 | 92.68 | 12.02 | 1.48 | 0.80 | 0.11 |
| Revenue Growth | -3.95% | 35.29% | 40.57% | 45.8% | 59.12% | 671.1% | 712.09% | 84.31% | 657.55% | - |
| Gross Profit | 376 | 394 | 287 | 203 | 139 | 86.92 | 10.92 | 1.48 | 0.80 | 0.11 |
| Operating Income | 149 | 144 | 99.54 | 54.22 | 20.84 | -5.28 | -61.92 | -42.17 | -37.75 | -40.12 |
| Net Income | 113 | 111 | 57.28 | 91.22 | 13.94 | -10.93 | -92.27 | -46.28 | 53.82 | -38.46 |
| Shares Outstanding | 52.41 | 51.99 | 50.76 | 49.47 | 47.49 | 42.26 | 31.85 | 17.44 | 1.61 | 1.59 |
| Earnings Per Share | 2.10 | 2.05 | 1.08 | 1.76 | 0.28 | -0.26 | -2.90 | -2.72 | 31.39 | -26.38 |
| EPS Growth | 2.44% | 89.81% | -38.64% | 528.57% | - | - | - | - | - | - |
| Operating Cash Flow | 143 | 129 | 115 | 66.81 | 34.52 | -24.50 | -57.95 | -47.20 | -36.19 | -32.54 |
| Capital Expenditures | -2.74 | -0.84 | -2.03 | -1.60 | -2.10 | -0.59 | -1.65 | -0.75 | -0.69 | -0.29 |
| Free Cash Flow | 140 | 128 | 113 | 65.21 | 32.42 | -25.09 | -59.60 | -47.95 | -36.87 | -32.84 |
| Cash & Equivalents | 347 | 356 | 140 | 90.12 | 62.19 | 74.34 | 82.19 | 88.51 | 48.79 | 32.97 |
| Total Debt | 376 | 329 | - | 4.17 | 7.09 | 26.22 | 34.39 | 22.90 | 29.49 | - |
| Net Cash / Debt | -28.54 | 26.56 | 140 | 85.96 | 55.11 | 48.11 | 47.80 | 65.61 | 19.30 | 32.97 |
| Assets | 1,160 | 978 | 424 | 310 | 189 | 137 | 111 | 93.99 | 53.73 | 47.01 |
| Liabilities | 565 | 525 | 157 | 118 | 101 | 96.09 | 77.53 | 36.42 | 44.29 | 91.33 |
| Book Value | 595 | 453 | 267 | 192 | 88.01 | 40.70 | 33.46 | 57.57 | 9.44 | -44.32 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Supernus Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
464 |
| CEO |
Jack A. Khattar |
Stock Information
| Ticker Symbol |
SUPN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: SUPN |
| IPO Date |
May 1, 2012 |
Description
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.